ABIM Cardiology common mistakes
ABIM Cardiology · Understand the traps and how to avoid them.
For a stable-angina vignette, picks percutaneous coronary intervention or bypass surgery as the answer before checking whether the patient is already on maximally tolerated antianginal therapy and risk-factor control.
The stem supplies a vivid symptom description and an abnormal stress test, which pattern-matches reflexively to 'cath.' Candidates also conflate the small set of stable-CAD anatomic indications that improve survival with the much larger set that only relieve symptoms.
What to do instead
Memorize the survival-benefit indications separately (left main stenosis, three-vessel disease with depressed LV function, proximal LAD with extensive ischemia) and treat everything else as symptom-limited. Before answering, scan the stem for 'despite' or 'maximally tolerated' language, which signals the guideline-directed-medical-therapy option is being tested.
Selects a complete heart failure regimen or withholds a drug purely from the ejection fraction, and never screens the vignette for reversible or treatable contributors such as iron deficiency, alcohol, tachyarrhythmia, or infiltrative disease.
Heart failure questions look like prescribing questions, so candidates lock onto the EF and stop reading. Modern four-pillar therapy plus SGLT2 inhibitors for mid-range and preserved EF have blurred the old EF-only algorithm, and infiltrative disease often presents with a preserved EF a trainee reads as 'just HFpEF.'
What to do instead
Replace 'EF equals therapy' with a two-step routine: first ask what could be causing or worsening the cardiomyopathy (iron studies, alcohol history, thyroid, sleep apnea, persistent tachyarrhythmia, amyloid red flags like low voltage with thick walls or bilateral carpal tunnel), then ask which guideline drugs apply. In a preserved-EF stem with unexplained hypertrophy, consider advanced imaging before committing.
In a regular wide-complex tachycardia, especially with a prior myocardial infarction, chooses adenosine or verapamil as the first maneuver rather than treating the rhythm as ventricular tachycardia.
Trainees learn that SVT with aberrancy exists and look for subtle morphology criteria to distinguish it, which encourages diagnostic hedging in a patient who may be unstable. Exam stems deliberately withhold confirmatory features so the safe default feels unsatisfying.
What to do instead
Adopt a hard rule: any wide-complex tachycardia is ventricular tachycardia until proven otherwise, and unstable patients get synchronized cardioversion. Adenosine is acceptable only for a stable, regular, monomorphic tachycardia when both diagnoses are genuinely plausible and the patient has no structural heart disease; verapamil is never the test answer in a wide-complex rhythm.
Recommends surgery for every patient labeled 'severe' aortic stenosis or mitral regurgitation, without checking whether the patient is symptomatic and without applying the ejection-fraction and cavity-size triggers used for asymptomatic disease.
The word 'severe' feels decisive, and murmur-plus-severity is the most rehearsed association in valvular disease. Candidates underweight the fact that asymptomatic severe disease is usually watched, and forget the numeric thresholds that justify earlier intervention.
What to do instead
Before answering, establish two facts explicitly: symptoms (including exertional intolerance the patient may have attributed to age) and the exact numbers. For asymptomatic severe primary mitral regurgitation, recall the triggers of ejection fraction at or below 60 percent, left ventricular end-systolic dimension at or above 40 mm, new atrial fibrillation, or pulmonary pressure above 50 mmHg. For asymptomatic severe aortic stenosis, intervention requires a symptom, a falling ejection fraction, or a positive exercise provocation.
Distinguishes constrictive pericarditis from restrictive cardiomyopathy by history and chest imaging alone, or offers anti-inflammatory therapy as the answer for established constriction, without using the Doppler and hemodynamic findings that separate them.
Both present with right heart failure, preserved ejection fraction, and biatrial enlargement, so candidates collapse them into one category and pick whichever disease name appears in their memory of the classic presentation. The discriminating findings are technical and easy to skip under time pressure.
What to do instead
Anchor the distinction in physiology: look for ventricular interdependence (septal bounce or shudder, respiratory variation in mitral inflow, annulus reversus, hepatic vein expiratory flow reversal) and, when needed, simultaneous right and left heart catheterization showing discordant pressure changes with respiration. Then remember that anti-inflammatory drugs treat early pericarditis, whereas chronic constriction requires pericardiectomy when symptoms persist.
In a patient with markedly elevated blood pressure but no acute end-organ injury, chooses intravenous labetalol or nitroprusside with the goal of rapid normalization over the first hours.
The stem's alarming blood pressure number drives the answer, and candidates do not separate hypertensive urgency from hypertensive emergency. There is also a vague belief that 'very high' pressures must come down fast, ignoring cerebral and coronary autoregulation.
What to do instead
Ask one question first: is there target-organ injury (encephalopathy, aortic dissection, pulmonary edema, acute coronary syndrome, acute kidney injury, retinal hemorrhage)? If no, this is urgency, treated with oral titration and outpatient follow-up. If yes, lower mean arterial pressure by roughly 10 to 20 percent in the first hour, then gradually, with the exception of aortic dissection, where rapid control of heart rate and pressure is required.
Initiates a parenteral prostacyclin for a new pulmonary arterial hypertension diagnosis without first confirming vasoreactivity status or excluding chronic thromboembolic pulmonary hypertension with imaging.
Pulmonary arterial hypertension questions reward recognizing the disease, so candidates jump to the most aggressive therapy. Chronic thromboembolic disease is the treatable mimic, and acute vasoreactivity testing is a specific, testable step that gets skipped.
What to do instead
Run the evaluation sequence before choosing therapy: confirm precapillary hemodynamics, obtain ventilation-perfusion scanning to exclude chronic thromboembolic pulmonary hypertension (consider referral for endarterectomy or balloon angioplasty), then perform acute vasoreactivity testing, reserving high-dose calcium channel blockers for true responders and combination therapy for the rest.
Recommends closure of an atrial septal defect or ventricular septal defect on the basis of the murmur and defect size, in a patient whose examination shows cyanosis, clubbing, or a loud pulmonic component with a soft or absent murmur.
Congenital lesion questions are taught as anatomy and shunt direction, but the decision to close depends on pulmonary vascular resistance. Eisenmenger physiology is presented subtly, and candidates read cyanosis as a reason to close rather than a contraindication.
What to do instead
Interpret the shunt by oxygen saturation and pressures, not by murmur loudness: in Eisenmenger syndrome the murmur of the defect disappears as pressures equalize, and differential cyanosis points to ductal disease. Verify pulmonary vascular resistance reversibility at catheterization before recommending closure, and remember that pregnancy is contraindicated with Eisenmenger physiology.
Withholds a statin because the calculated ten-year atherosclerotic risk is borderline, without considering risk-enhancing factors or the role of coronary calcium scoring.
Candidates treat the calculator output as the final determinant and forget the intermediate-risk pathway, where treatment decisions are explicitly meant to be refined by additional data.
What to do instead
Build a forced intermediate-risk step into your reasoning: if ten-year risk is in the borderline-to-intermediate range, review risk enhancers (family history of premature disease, persistent elevated triglycerides, chronic inflammatory disease, South Asian ancestry, premature menopause, elevated lipoprotein(a)), discuss shared decision-making, and use coronary artery calcium to reclassify: zero favors deferring, and a high score favors starting therapy.
Orders stress testing before every noncardiac operation and starts a beta blocker on the morning of surgery to 'protect' the patient.
Perioperative questions still carry habits from old algorithms, and candidates confuse a risk estimate with an indication for ischemia testing. The beta-blocker answer is memorably associated with improved outcomes, but the timing nuance is what gets tested.
What to do instead
Use a stepwise approach: estimate risk with a validated index, confirm the patient's functional capacity, and reserve stress testing only when it would change management in a patient with poor or unknown capacity undergoing elevated-risk surgery. Continue beta blockers already prescribed, but never initiate one on the day of surgery; if starting, do so days to weeks ahead with dose titration.